1
|
Lee SS, Park JS, Lee KB, Jeong DH, Byun JM, Lee SM. Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer. Asian Pac J Cancer Prev 2021; 22:1123-1127. [PMID: 33906304 PMCID: PMC8325115 DOI: 10.31557/apjcp.2021.22.4.1123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Indexed: 11/25/2022] Open
Abstract
OBJECTIVE This study aimed to examine the diagnostic performance of F-18 fluorodeoxyglucose positron emission tomography with computed tomography (F-18 FDG PET/CT) compared with cancer antigen 125 (CA125), human epididymis protein 4 (HE4), and risk of ovarian malignancy algorithm (ROMA) score to distinguish epithelial ovarian cancer from benign tumors. METHODS A total of 46 patients with pelvic masses, who underwent F-18 FDG PET/CT, CA125, and HE4 before surgery between January 2015 and December 2018, were included in this retrospective study. The diagnostic performance of CA125, HE4, ROMA score, and maximum standardized uptake value (SUVmax) to differentiate epithelial ovarian cancer from benign pelvic tumors was examined by receiver operating characteristic curve analysis. RESULTS Among the 46 patients, 28 were cases of ovarian cancers and 18 were of benign. The mean values of CA125, HE4, ROMA score, and SUVmax were significantly higher in the ovarian cancer group than the benign group. In early cancer stages (stages I and II), Area under the curve for SUVmax was significantly higher than CA125 and ROMA score (0.778 for CA125, 0.753 for HE4, 0.682 for ROMA score, and 0.922 for SUVmax). CONCLUSION SUVmax using F-18 FDG PET/CT showed a high diagnostic accuracy for differentiating epithelial ovarian cancer from benign pelvic tumors, including early stage ovarian cancer. F-18 FDG PET/CT can be a useful modality for the assessment of pelvic mass.<br />.
Collapse
Affiliation(s)
- Sun Seong Lee
- Department of Nuclear Medicine, Busan Paik Hospital, University of Inje College of Medicine, Busan, Republic of Korea
| | - Ji Sun Park
- Department of Nuclear Medicine, Busan Paik Hospital, University of Inje College of Medicine, Busan, Republic of Korea
| | - Kyung Bok Lee
- Department of Obstetrics & Gynecology, Busan Paik Hospital, University of Inje College of Medicine, Busan, Republic of Korea
| | - Dae Hoon Jeong
- Department of Obstetrics & Gynecology, Busan Paik Hospital, University of Inje College of Medicine, Busan, Republic of Korea
| | - Jung Mi Byun
- Department of Obstetrics & Gynecology, Busan Paik Hospital, University of Inje College of Medicine, Busan, Republic of Korea
| | - Seok Mo Lee
- Department of Nuclear Medicine, Busan Seongso Hospital, Busan, Republic of Korea
| |
Collapse
|
2
|
Lu Y, Li M, Massicano AVF, Song PN, Mansur A, Heinzman KA, Larimer BM, Lapi SE, Sorace AG. [ 89Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models. Molecules 2021; 26:1568. [PMID: 33809310 PMCID: PMC8001650 DOI: 10.3390/molecules26061568] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Accepted: 03/09/2021] [Indexed: 12/19/2022] Open
Abstract
Paclitaxel (PTX) treatment efficacy varies in breast cancer, yet the underlying mechanism for variable response remains unclear. This study evaluates whether human epidermal growth factor receptor 2 (HER2) expression level utilizing advanced molecular positron emission tomography (PET) imaging is correlated with PTX treatment efficacy in preclinical mouse models of HER2+ breast cancer. HER2 positive (BT474, MDA-MB-361), or HER2 negative (MDA-MB-231) breast cancer cells were subcutaneously injected into athymic nude mice and PTX (15 mg/kg) was administrated. In vivo HER2 expression was quantified through [89Zr]-pertuzumab PET/CT imaging. PTX treatment response was quantified by [18F]-fluorodeoxyglucose ([18F]-FDG) PET/CT imaging. Spearman's correlation, Kendall's tau, Kolmogorov-Smirnov test, and ANOVA were used for statistical analysis. [89Zr]-pertuzumab mean standard uptake values (SUVmean) of BT474 tumors were 4.9 ± 1.5, MDA-MB-361 tumors were 1.4 ± 0.2, and MDA-MB-231 (HER2-) tumors were 1.1 ± 0.4. [18F]-FDG SUVmean changes were negatively correlated with [89Zr]-pertuzumab SUVmean (r = -0.5887, p = 0.0030). The baseline [18F]-FDG SUVmean was negatively correlated with initial [89Zr]-pertuzumab SUVmean (r = -0.6852, p = 0.0002). This study shows PTX treatment efficacy is positively correlated with HER2 expression level in human breast cancer mouse models. Molecular imaging provides a non-invasive approach to quantify biological interactions, which will help in identifying chemotherapy responders and potentially enhance clinical decision-making.
Collapse
Affiliation(s)
- Yun Lu
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (Y.L.); (M.L.); (A.V.F.M.); (P.N.S.); (B.M.L.); (S.E.L.)
- Graduate Biomedical Sciences, University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Meng Li
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (Y.L.); (M.L.); (A.V.F.M.); (P.N.S.); (B.M.L.); (S.E.L.)
| | - Adriana V. F. Massicano
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (Y.L.); (M.L.); (A.V.F.M.); (P.N.S.); (B.M.L.); (S.E.L.)
| | - Patrick N. Song
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (Y.L.); (M.L.); (A.V.F.M.); (P.N.S.); (B.M.L.); (S.E.L.)
| | - Ameer Mansur
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (A.M.); (K.A.H.)
| | - Katherine A. Heinzman
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (A.M.); (K.A.H.)
| | - Benjamin M. Larimer
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (Y.L.); (M.L.); (A.V.F.M.); (P.N.S.); (B.M.L.); (S.E.L.)
- O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Suzanne E. Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (Y.L.); (M.L.); (A.V.F.M.); (P.N.S.); (B.M.L.); (S.E.L.)
- Graduate Biomedical Sciences, University of Alabama at Birmingham, Birmingham, AL 35233, USA
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (A.M.); (K.A.H.)
- O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA
- Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Anna G. Sorace
- Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (Y.L.); (M.L.); (A.V.F.M.); (P.N.S.); (B.M.L.); (S.E.L.)
- Graduate Biomedical Sciences, University of Alabama at Birmingham, Birmingham, AL 35233, USA
- Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35233, USA; (A.M.); (K.A.H.)
- O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA
| |
Collapse
|
3
|
Supuran CT. Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors. J Exp Pharmacol 2020; 12:603-617. [PMID: 33364855 DOI: 10.2147/jep.s265620] [Citation(s) in RCA: 63] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Accepted: 11/28/2020] [Indexed: 12/18/2022] Open
Abstract
Carbonic anhydrase (CA, EC 4.2.1.1) isoforms IX and XII are overexpressed in many hypoxic tumors as a consequence of the hypoxia inducible factor (HIF) activation cascade, being present in limited amounts in normal tissues. These enzymes together with many others are involved in the pH regulation and metabolism of hypoxic cancer cells, and were validated as antitumor targets recently. A multitude of targeting strategies against these enzymes have been proposed and are reviewed in this article. The small molecule inhibitors, small molecule drug conjugates (SMDCs), antibody-drug conjugates (ADACs) or cytokine-drug conjugates but not the monoclonal antibodies against CA IX/XII will be discussed. Relevant synthetic chemistry efforts, coupled with a multitude of preclinical studies, demonstrated that CA IX/XII inhibition leads to the inhibition of growth of primary tumors and metastases and depletes cancer stem cell populations, all factors highly relevant in clinical settings. One small molecule inhibitor, sulfonamide SLC-0111, is the most advanced candidate, having completed Phase I and being now in Phase Ib/II clinical trials for the treatment of advanced hypoxic solid tumors.
Collapse
Affiliation(s)
- Claudiu T Supuran
- Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence, Florence 50019, Italy
| |
Collapse
|
4
|
Avan Z, Biabani Ardakani J, Talebpour Amiri F, Abedi SM, Hosseinimehr SJ. The Potential Usefulness of 99mTc-HYNIC-(Ser)3-LTVPWY Peptide for Predicting HER2 Status Alteration After Chemotherapy in Ovarian Tumor-Bearing Mice. Cancer Biother Radiopharm 2020; 37:862-869. [DOI: 10.1089/cbr.2020.4004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Affiliation(s)
- Zahra Avan
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
- Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
| | - Javad Biabani Ardakani
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| | - Fereshteh Talebpour Amiri
- Department of Anatomy and Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Seyed Mohammad Abedi
- Department of Radiology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
| | - Seyed Jalal Hosseinimehr
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
| |
Collapse
|
5
|
Sun Y, Sun Y, Qin Y, Zhang Y, Yuan H, Yang Z. ‘Virtual experience’ as an intervention before a positron emission tomography/CT scan may ease patients’ anxiety and improve image quality. J Med Imaging Radiat Oncol 2020; 64:641-648. [DOI: 10.1111/1754-9485.13078] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 05/11/2020] [Accepted: 05/28/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Yuyun Sun
- Department of Nuclear Medicine Fudan University Shanghai Cancer Center Shanghai China
- Department of Oncology Shanghai Medical College Fudan University Shanghai China
- Center for Biomedical Imaging Fudan University Shanghai China
- Shanghai Engineering Research Center of Molecular Imaging Probes Shanghai China
| | - Yifei Sun
- Department of Nuclear Medicine Fudan University Shanghai Cancer Center Shanghai China
- Department of Oncology Shanghai Medical College Fudan University Shanghai China
- Center for Biomedical Imaging Fudan University Shanghai China
- Shanghai Engineering Research Center of Molecular Imaging Probes Shanghai China
| | - Yue Qin
- Department of Nuclear Medicine Fudan University Shanghai Cancer Center Shanghai China
- Department of Oncology Shanghai Medical College Fudan University Shanghai China
- Center for Biomedical Imaging Fudan University Shanghai China
- Shanghai Engineering Research Center of Molecular Imaging Probes Shanghai China
| | - Yingjian Zhang
- Department of Nuclear Medicine Fudan University Shanghai Cancer Center Shanghai China
- Department of Oncology Shanghai Medical College Fudan University Shanghai China
- Center for Biomedical Imaging Fudan University Shanghai China
- Shanghai Engineering Research Center of Molecular Imaging Probes Shanghai China
| | - Huiyu Yuan
- Department of Nuclear Medicine Fudan University Shanghai Cancer Center Shanghai China
- Department of Oncology Shanghai Medical College Fudan University Shanghai China
- Center for Biomedical Imaging Fudan University Shanghai China
- Shanghai Engineering Research Center of Molecular Imaging Probes Shanghai China
| | - Zhongyi Yang
- Department of Nuclear Medicine Fudan University Shanghai Cancer Center Shanghai China
- Department of Oncology Shanghai Medical College Fudan University Shanghai China
- Center for Biomedical Imaging Fudan University Shanghai China
- Shanghai Engineering Research Center of Molecular Imaging Probes Shanghai China
| |
Collapse
|
6
|
Abstract
Molecular imaging with positron emission tomography (PET) using tumour-seeking radiopharmaceuticals has gained wide acceptance in oncology with many clinical applications. The hybrid imaging modality PET/CT (computed tomography) allows assessing molecular as well as morphologic information at the same time. Therefore, PET/CT represents an efficient tool for whole-body staging and re-staging within one imaging modality. In oncology, the glucose analogue 18-F-fluorodeoxyglucose (FDG) is the most widely used PET/CT radiopharmaceutical in clinical routine. FDG PET and FDG PET/CT have been used for staging and re-staging of tumour patients in numerous studies. This chapter will discuss the use and the main indications of FDG PET/CT in oncology with special emphasis on lung cancer, lymphoma, head and neck cancer, melanoma and breast cancer (among other tumour entities). A review of the current literature is given with respect to primary diagnosis, staging and diagnosis of recurrent disease. Besides its integral role in diagnosis, staging and re-staging of disease in oncology, there is increasing evidence that FDG PET/CT can be used for therapy response assessment (possibly influencing therapeutic management and treatment planning) by evaluating tumour control, which will also be discussed in this chapter.
Collapse
Affiliation(s)
- Juliane Becker
- Department of Nuclear Medicine, University Medicine Rostock, Gertrudenplatz 1, 18057, Rostock, Germany
| | - Sarah M Schwarzenböck
- Department of Nuclear Medicine, University Medicine Rostock, Gertrudenplatz 1, 18057, Rostock, Germany
| | - Bernd J Krause
- Department of Nuclear Medicine, University Medicine Rostock, Gertrudenplatz 1, 18057, Rostock, Germany.
| |
Collapse
|
7
|
Potential Prognostic Role of 18F-FDG PET/CT in Invasive Epithelial Ovarian Cancer Relapse. A Preliminary Study. Cancers (Basel) 2019; 11:cancers11050713. [PMID: 31126127 PMCID: PMC6562912 DOI: 10.3390/cancers11050713] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 05/18/2019] [Accepted: 05/21/2019] [Indexed: 12/13/2022] Open
Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, with relapse occurring in about 70% of advanced cases with poor prognosis. Fluorine-18-2-fluoro-2-deoxy-d-glucose PET/CT (18F-FDGPET/CT) is the most specific radiological imaging used to assess recurrence. Some intensity-based and volume-based PET parameters, maximum standardized uptake values (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG), are indicated to have a correlation with treatment response. The aim of our study is to correlate these parameters with post relapse survival (PRS) and overall survival (OS) in Epithelial Ovarian Cancer (EOC) relapse. The study included 50 patients affected by EOC relapse who underwent 18F-FDGPET/CT before surgery. All imaging was reviewed and SUVmax, MTV and TLG were calculated and correlated to PRS and OS. PRS and OS were obtained from the first relapse and from the first diagnosis to the last follow up or death, respectively. SUVmax, MTV and TLG were tested in a univariate logistic regression analysis, only SUVmax demonstrated to be significantly associated to PRS and OS (p = 0.005 and p = 0.024 respectively). Multivariate analysis confirmed the results. We found a cut-off of SUVmax of 13 that defined worse or better survival (p = 0.003). In the first relapse of EOC, SUVmax is correlated to PRS and OS, and when SUVmax is greater than 13, it is an unfavorable prognostic factor.
Collapse
|
8
|
Castellani F, Nganga EC, Dumas L, Banerjee S, Rockall AG. Imaging in the pre-operative staging of ovarian cancer. Abdom Radiol (NY) 2019; 44:685-696. [PMID: 30229424 DOI: 10.1007/s00261-018-1779-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The main prognostic factor in ovarian cancer is the stage of disease at diagnosis. The staging system in use (FIGO classification, updated in 2014) is based on the surgical-pathological findings. Although surgical staging is the gold standard in ovarian cancer, the initial patient management depends on the imaging-based pre-surgical staging assessment, in order to identify unresectable or difficult to resect disease. Radiologists need to be aware of the strengths of the available imaging modalities, as well as the imaging pitfalls. Clear understanding of pattern of disease spread and review areas are critical for accurate staging and treatment planning. The current standard of care for pre-surgical staging is CT of the thorax, abdomen, and pelvis. This allows a rapid evaluation of disease extent and is fairly accurate in identifying bulky disease but has definite limitations in assessing the extent of small volume disease and in the confirmation of certain sites of disease beyond the abdomen. Functional MRI has been reported to be superior in detecting small peritoneal deposits. PET/CT may be used as a problem-solving tool in some patients where determination remains unclear, particularly in confirmation of advanced stage beyond the abdomen.
Collapse
Affiliation(s)
- Francesca Castellani
- Department of Diagnostic Radiology, Royal Marsden NHS Foundation Trust, Fulham Rd., London, SW3 6JJ, UK.
- Department of Diagnostic Radiology and Interventional Radiology, Policlinico Tor Vergata, Viale Oxford 81, 00100, Rome, Italy.
| | - Edward C Nganga
- Department of Diagnostic Radiology, Royal Marsden NHS Foundation Trust, Fulham Rd., London, SW3 6JJ, UK
| | - Lucy Dumas
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, Fulham Rd., London, SW3 6JJ, United Kingdom
| | - Susana Banerjee
- Gynaecology Unit, The Royal Marsden NHS Foundation Trust, Fulham Rd., London, SW3 6JJ, United Kingdom
| | - Andrea G Rockall
- Department of Diagnostic Radiology, Royal Marsden NHS Foundation Trust, Fulham Rd., London, SW3 6JJ, UK
- Division of Surgery and Cancer, Imperial College London, London, United Kingdom
| |
Collapse
|
9
|
Rubello D, Marzola MC, Colletti PM. Re: The Prognostic Value of 18F-FDG PET/CT in Monitoring Chemotherapy in Ovarian Cancer Both at Initial Diagnosis and at Recurrent Disease. Clin Nucl Med 2018; 44:342-344. [PMID: 30371573 DOI: 10.1097/rlu.0000000000002318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Domenico Rubello
- Nuclear Medicine and PET Unit Department of Molecular Imaging Radiology, and Clinical Pathology Rovigo Hospital Rovigo,
| | - Maria Cristina Marzola
- Nuclear Medicine and PET Unit Department of Molecular Imaging Radiology, and Clinical Pathology Rovigo Hospital Rovigo,
| | - Patrick M Colletti
- Department of Nuclear Medicine University of Southern California Los Angeles, CA
| |
Collapse
|